Increased heart rate (HR) is a reaction to head-to-toe gravito-inertial (G) force. The anti-G straining manoeuvre (AGSM) is the crucial technique for withstanding a high-G load. Previous studies reported the main effects of HR only or AGSM only on G tolerance. We assessed the combined effect of HR and AGSM on the outcome of 9G profile exposure. A total of 530 attempts for the 9G profile were extracted to clarify the association of interest. Subjects with an AGSM effectiveness of less than 2.5G had a 2.14-fold higher likelihood of failing in the 9G profile. Trainees with HR increases of less than 20% in the first five seconds also had higher odds of 9G profile intolerance (adjusted OR 1.83, 95% CI 1.09-3.07). The adjusted OR of 9G profile disqualification was 2.93 (95% CI 1.19-7.20) for participants with smaller HR increases and lower AGSM effectiveness. The negative effect of a smaller HR increase on the outcome was likely to be affected by improved AGSM effectiveness (adjusted OR 1.26, 95% CI 0.65-2.42). We speculate that low AGSM effectiveness and a small HR increase were separately associated with failure of high-G challenge. Nonetheless, good AGSM performance seemed to reduce the negative effect of weak HR responses on the dependent variable.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730161 | PMC |
http://dx.doi.org/10.1038/s41598-020-78687-3 | DOI Listing |
Introduction: During centrifuge-simulated suborbital spaceplane flights, launch and re-entry frequently cause visual symptoms, and G-induced loss of consciousness can occur. G-related effects may be more prominent during re-entry from microgravity on actual flights. A modified anti-G maneuver that does not involve a breath strain and is suitable for members of the public may be effective against these effects.
View Article and Find Full Text PDFSci Rep
November 2024
Centre for Healthy Brain Ageing, Discipline of Psychiatry and Mental Health, School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, NSW, Australia.
Beneficial associations between higher fruit and vegetable intakes and risk of depression appear to exist but few studies have focused on adults aged 45 + years and the potential that associations are due to residual confounding has not been tested. This longitudinal study of twins (n = 3483, age 45-90 years) from Australia, Denmark, Sweden and USA, assessed the associations between baseline fruit/vegetable intake and depressive symptoms over 5-11 years using linear mixed effects models. Intakes from food frequency questionnaires were trichotomized.
View Article and Find Full Text PDFFront Public Health
September 2024
CIC INSERM 1424, Cayenne Hospital, Cayenne, French Guiana.
Several countries of the Guiana Shield are aiming at the control and elimination of malaria in areas where Artisanal and Small-scale Gold Mining (ASGM) activities predominate, raising questions about how to strengthen community engagement to improve the effectiveness of health programs. The Curema project focuses its intervention on the mobile and hard-to-reach ASGM population, complementing the efforts of national programs in the Guiana Shield. The Curema intervention combines targeted drug administration for suspected asymptomatic carriers, the Malakit distribution, and health education activities.
View Article and Find Full Text PDFJ Geriatr Oncol
March 2024
Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, 119-143 Missenden Road, Camperdown, NSW 2050, Australia; School of Medicine, The University of Sydney, Camperdown, NSW 2006, Australia.
Introduction: Consolidation durvalumab following platinum-based chemoradiotherapy (CRT) significantly improved overall survival for patients with unresectable stage III non-small cell lung cancer (NSCLC) in the PACIFIC trial. However, older patients were underrepresented in PACIFIC, and subsequent analyses suggested trends toward poorer survival and increased toxicity in patients aged ≥70 years old. We assessed the effectiveness and safety of consolidation durvalumab following CRT in older Australian patients with unresectable stage III NSCLC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!